<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pers Med</journal-id><journal-id journal-id-type="iso-abbrev">J Pers Med</journal-id><journal-id journal-id-type="pmc-domain-id">2605</journal-id><journal-id journal-id-type="pmc-domain">jpersmed</journal-id><journal-id journal-id-type="publisher-id">jpm</journal-id><journal-title-group><journal-title>Journal of Personalized Medicine</journal-title></journal-title-group><issn pub-type="epub">2075-4426</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11943274</article-id><article-id pub-id-type="pmcid-ver">PMC11943274.1</article-id><article-id pub-id-type="pmcaid">11943274</article-id><article-id pub-id-type="pmcaiid">11943274</article-id><article-id pub-id-type="pmid">40137405</article-id><article-id pub-id-type="doi">10.3390/jpm15030089</article-id><article-id pub-id-type="publisher-id">jpm-15-00089</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Association of Aspirin Use in Primary Prevention and Cardiovascular Events: A Retrospective Analysis of the VITAL Cohort</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2520-5673</contrib-id><name name-style="western"><surname>Caldeira</surname><given-names initials="D">Daniel</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x2013; original draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x2013; review &amp; editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-jpm-15-00089" ref-type="aff">1</xref><xref rid="af2-jpm-15-00089" ref-type="aff">2</xref><xref rid="af3-jpm-15-00089" ref-type="aff">3</xref><xref rid="af4-jpm-15-00089" ref-type="aff">4</xref><xref rid="c1-jpm-15-00089" ref-type="corresp">*</xref><xref rid="fn1-jpm-15-00089" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1369-8423</contrib-id><name name-style="western"><surname>Alves</surname><given-names initials="M">Mariana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x2013; original draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af4-jpm-15-00089" ref-type="aff">4</xref><xref rid="af5-jpm-15-00089" ref-type="aff">5</xref><xref rid="fn1-jpm-15-00089" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gon&#231;alves</surname><given-names initials="N">Nilza</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x2013; review &amp; editing/">Writing &#8211; review &amp; editing</role><xref rid="af4-jpm-15-00089" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5831-4921</contrib-id><name name-style="western"><surname>Costa</surname><given-names initials="J">Jo&#227;o</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x2013; review &amp; editing/">Writing &#8211; review &amp; editing</role><xref rid="af4-jpm-15-00089" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3950-5113</contrib-id><name name-style="western"><surname>Ferreira</surname><given-names initials="JJ">Joaquim J.</given-names></name><xref rid="af4-jpm-15-00089" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8034-4529</contrib-id><name name-style="western"><surname>Pinto</surname><given-names initials="FJ">Fausto J.</given-names></name><xref rid="af1-jpm-15-00089" ref-type="aff">1</xref><xref rid="af2-jpm-15-00089" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Pritzker</surname><given-names initials="KPH">Kenneth P.H.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Kalogeropoulos</surname><given-names initials="AP">Andreas P.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jpm-15-00089"><label>1</label>Centro Cardiovascular da Universidade de Lisboa&#8212;CCUL@RISE, Centro Acad&#233;mico de Medicina de Lisboa (CAML), Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal; <email>faustopinto@medicina.ulisboa.pt</email></aff><aff id="af2-jpm-15-00089"><label>2</label>Cardiology Department, Hospital Universit&#225;rio de Santa Maria&#8212;ULS Santa Maria (ULSSM), 1649-035 Lisbon, Portugal</aff><aff id="af3-jpm-15-00089"><label>3</label>Centro de Estudos de Medicina Baseada na Evid&#234;ncia (CEMBE), Faculdade de Medicina, Universidade de Lisboa, 1649-029 Lisbon, Portugal</aff><aff id="af4-jpm-15-00089"><label>4</label>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, 1649-029 Lisbon, Portugal; <email>marianaalves88@gmail.com</email> (M.A.); <email>nilzakarina@gmail.com</email> (N.G.); <email>jcosta.fml@gmail.com</email> (J.C.); <email>joaquimjferreira@gmail.com</email> (J.J.F.)</aff><aff id="af5-jpm-15-00089"><label>5</label>Servi&#231;o de Medicina, ULS Santa Maria (ULSSM), 1649-035 Lisboa, Portugal</aff><author-notes><corresp id="c1-jpm-15-00089"><label>*</label>Correspondence: <email>dgcaldeira@hotmail.com</email></corresp><fn id="fn1-jpm-15-00089"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>15</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">485319</issue-id><elocation-id>89</elocation-id><history><date date-type="received"><day>01</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>31</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>27</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-27 18:25:14.187"><day>27</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jpm-15-00089.pdf"/><abstract><p><bold>Background:</bold> Aspirin is part of the therapeutic antithrombotic armamentarium for the management of patients with established clinically relevant atherosclerosis or thrombotic cardiovascular disease. Personalized medicine identifies those who benefit most or face fewer risks from aspirin. The role of aspirin in primary prevention is still debatable. We aimed to assess the risks and benefits of aspirin in this setting, using the data of the prospective VITAL (VITamins and Lifestyle) study. <bold>Methods:</bold> We conducted a retrospective evaluation of the VITAL cohort. In this analysis, participants were split according to aspirin usage. Aspirin use was evaluated regarding all-cause mortality, CV mortality, major cardiovascular event (MACE), myocardial infarction, coronary heart disease, total stroke, and hemorrhagic stroke. The hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated to explore the association between cardiovascular events and aspirin usage. The estimates were adjusted for demographic and clinical variables. <bold>Results:</bold> The aspirin users (<italic toggle="yes">n</italic> = 11,570) were older, more frequently men, the body mass index was higher, and the proportion of smokers was smaller compared with non-users (<italic toggle="yes">n</italic> = 13,927). After adjusting for demographic and clinical variables, aspirin was not identified as a predictor of cardiovascular death (HR 1.17, 95%CI 0.89 to 1.55), major cardiovascular events (HR 1.04, 95%CI 0.89 to 1.22), coronary heart disease (HR 1.16, 95%CI 0.98 to 1.37), nor stroke (HR 1.01, 95%CI 0.77 to 1.31). <bold>Conclusion:</bold> In this retrospective analysis of the VITAL cohort, aspirin was not associated with a reduced risk of cardiovascular mortality or events.</p></abstract><kwd-group><kwd>cardiovascular disease</kwd><kwd>primary prevention</kwd><kwd>aspirin</kwd><kwd>atherothrombotic disease</kwd><kwd>antiplatelet therapy</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-jpm-15-00089"><title>1. Introduction</title><p>Antiplatelet treatment is a cornerstone in the management of patients with established atherosclerotic cardiovascular disease (ASCVD), effectively reducing the risk of recurrent cardiovascular events. Aspirin, the most common antiplatelet agent, acts by inhibiting the production of thromboxane, a molecule responsible for platelet aggregation and thrombus formation. Aspirin is widely available without a prescription, typically as 300 mg tablets, and is commonly used as an anti-inflammatory drug for minor aches, pains, and fever reduction. Low-dose aspirin (usually 75 mg) is widely used in cardiovascular and cerebrovascular prevention, helping to reduce the risk of heart attacks, strokes, and blood clots in high-risk individuals. In addition, aspirin is used in obstetric care to prevent complications such as pre-eclampsia in pregnant women at elevated risk [<xref rid="B1-jpm-15-00089" ref-type="bibr">1</xref>].</p><p>Antiplatelet drugs are recommended for the secondary prevention of cardio- and cerebrovascular disease. However, its role in primary prevention remains controversial and challenging to define [<xref rid="B2-jpm-15-00089" ref-type="bibr">2</xref>,<xref rid="B3-jpm-15-00089" ref-type="bibr">3</xref>,<xref rid="B4-jpm-15-00089" ref-type="bibr">4</xref>]. This controversy arises from the delicate balance between its modest cardiovascular benefits and the potential for serious adverse events, particularly bleeding complications. Contemporary meta-analyses have demonstrated that while aspirin use in primary prevention may yield a small reduction in cardiovascular events, the accompanying increase in bleeding risk often outweighs the benefits, resulting in an uncertain net clinical benefit [<xref rid="B5-jpm-15-00089" ref-type="bibr">5</xref>,<xref rid="B6-jpm-15-00089" ref-type="bibr">6</xref>,<xref rid="B7-jpm-15-00089" ref-type="bibr">7</xref>,<xref rid="B8-jpm-15-00089" ref-type="bibr">8</xref>,<xref rid="B9-jpm-15-00089" ref-type="bibr">9</xref>,<xref rid="B10-jpm-15-00089" ref-type="bibr">10</xref>].</p><p>For primary prevention, these drugs are advised only in patients at very high risk but are not mandatory, as the balance between risk and benefit remains unsettled. In older individuals, the age-related risk of bleeding necessitates a careful risk/benefit evaluation before prescribing antiplatelet drugs, whether for primary or secondary cardiovascular prevention [<xref rid="B11-jpm-15-00089" ref-type="bibr">11</xref>].</p><p>In light of these findings, the guidelines from major cardiovascular societies have taken a cautious stance. The 2019 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend the infrequent use of aspirin in individuals without established ASCVD, given the lack of a clear net benefit [<xref rid="B12-jpm-15-00089" ref-type="bibr">12</xref>]. Similarly, the ESC guidelines for cardiovascular disease prevention advise against the routine use of antiplatelet therapy in individuals with low or moderate cardiovascular risk due to concerns over major bleeding, assigning a class III recommendation with level A evidence [<xref rid="B2-jpm-15-00089" ref-type="bibr">2</xref>]. These positions underscore the need for a more nuanced, patient-centered approach to aspirin therapy in primary prevention, taking into account the individual risk factors for both cardiovascular events and bleeding.</p><p>Personalized medicine approaches, integrating tools such as risk stratification scores and biomarker profiles, may help refine the identification of patients most likely to benefit from antiplatelet therapy [<xref rid="B13-jpm-15-00089" ref-type="bibr">13</xref>]. However, real-world data on this issue remain limited.</p><p>To address this knowledge gap, we conducted a post hoc analysis of the VITAL (VITamins and Lifestyle) cohort data, aiming to evaluate whether findings from randomized controlled trials regarding aspirin use are applicable to broader, non-trial populations. This analysis seeks to inform the ongoing debate surrounding aspirin therapy in primary prevention by providing insights into its benefits and risks in a real-world cohort.</p></sec><sec id="sec2-jpm-15-00089"><title>2. Materials and Methods</title><p>This study utilized retrospective data from the VITAL (VITamins and Lifestyle) cohort in a post hoc evaluation, made available through the Project Data Sphere platform (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.34949/n4c7-zm25">https://doi.org/10.34949/n4c7-zm25</uri>, accessed on 26 March 2024).</p><p>The VITAL study is a large, prospective cohort designed to investigate the associations between supplement use, cancer risk, and cardiovascular outcomes. Originally conducted in western Washington state, the study recruited participants between 2000 and 2002 and targeted men and women aged 50&#8211;76 years.</p><p>The cohort comprised 77,738 participants who completed detailed baseline questionnaires on supplement use, diet, and other cancer and cardiovascular risk factors. Additionally, 70% of participants provided self-collected buccal cell specimens for DNA analysis, enhancing the study&#8217;s potential for genetic and biomarker-based evaluations. However, these data were not utilized in our analysis.</p><p>In the original randomized controlled VITAL trial initiated in 2010, 25,871 participants were followed for a median of 5.3 years. The trial used a 2 &#215; 2 factorial design to assess the impact of vitamin D (2000 IU/day) and/or omega-3 fatty acid (1 g/day) supplementation on primary prevention of cancer and cardiovascular events.</p><sec sec-type="subjects" id="sec2dot1-jpm-15-00089"><title>2.1. Participants</title><p>The participants in the VITAL study were carefully selected to exclude individuals with a history of major cardiovascular or cancer events, including myocardial infarction, stroke, transient ischemic attack (TIA), coronary-artery bypass grafting (CABG), percutaneous coronary intervention, and cancer other than non-melanoma skin cancer.</p><p>Further exclusion criteria included renal failure requiring dialysis, hypercalcemia, parathyroid dysfunction, liver cirrhosis, and granulomatous diseases. Additionally, participants were asked to limit their use of supplemental vitamin D and calcium and abstain from fish oil supplements. These stringent inclusion and exclusion criteria ensured that the study focused on a healthy, at-risk population free from significant pre-existing comorbidities.</p><p>To assess the long-term outcomes, the study employed an efficient follow-up system using linkages to public databases for tracking cancer diagnoses, cardiovascular events, deaths, and changes in residence. This robust methodology minimized loss to follow-up and ensured comprehensive outcome capture [<xref rid="B14-jpm-15-00089" ref-type="bibr">14</xref>].</p></sec><sec id="sec2dot2-jpm-15-00089"><title>2.2. Outcomes</title><p>The data collection included baseline and follow-up questionnaires administered at 6 months, 12 months, and annually thereafter (for 6 years). In the randomized controlled component of the VITAL trial, the primary outcomes were cancer incidence and major cardiovascular adverse event (MACE), which included myocardial infarction, stroke, and death from cardiovascular causes. Cardiovascular deaths were confirmed using hospital records, autopsy reports, and death certificates, with outcome adjudication performed by a blinded committee of physicians [<xref rid="B14-jpm-15-00089" ref-type="bibr">14</xref>].</p><p>In this retrospective analysis, we explored the associations between aspirin use and several cardiovascular outcomes, including MACE&#8212;as defined before&#8212;expanded MACE (including MACE and coronary revascularization such as percutaneous coronary intervention or coronary artery bypass grafting), total myocardial infarction (MI), total coronary heart disease (CHD) (which included non-fatal MI, coronary revascularization, and CHD-related deaths), and total stroke and hemorrhagic stroke, classified according to the Trial of Org 10,172 in Acute Stroke Treatment (TOAST) criteria. To enhance reliability, outcomes such as myocardial infarction and stroke were defined using established clinical guidelines, including the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation criteria for myocardial infarction and the TOAST criteria for stroke [<xref rid="B15-jpm-15-00089" ref-type="bibr">15</xref>,<xref rid="B16-jpm-15-00089" ref-type="bibr">16</xref>,<xref rid="B17-jpm-15-00089" ref-type="bibr">17</xref>].</p></sec><sec id="sec2dot3-jpm-15-00089"><title>2.3. Supplement Use and Confounding Factors</title><p>The VITAL study targeted a population with a high prevalence of supplement use. At baseline, 66% of participants reported regular multivitamin use, while individual vitamin C, vitamin E, and calcium use was reported by approximately 46&#8211;47% of the cohort. The participants reported an average duration of supplement use spanning 5&#8211;8 years over the previous decade [<xref rid="B15-jpm-15-00089" ref-type="bibr">15</xref>].</p><p>Confounding factors were rigorously assessed, with strong associations observed between supplement use and other health behaviors, including regular nonsteroidal anti-inflammatory drug use, higher intake of fruits and vegetables, and increased recreational physical activity. These associations, although robust, presented challenges in disentangling direct effects from lifestyle influences [<xref rid="B14-jpm-15-00089" ref-type="bibr">14</xref>,<xref rid="B15-jpm-15-00089" ref-type="bibr">15</xref>].</p></sec><sec id="sec2dot4-jpm-15-00089"><title>2.4. Statistical Methods</title><p>Participants were stratified based on baseline aspirin usage into aspirin users and non-users. The descriptive statistics were calculated, with means and standard deviations used for continuous variables and absolute and relative frequencies for categorical variables.</p><p>Comparisons between groups were performed using independent sample t-tests for continuous variables and chi-square tests for categorical variables. To evaluate the association between aspirin use and the outcomes of interest, univariate and multivariate Cox proportional hazards regression models were employed. The hazard ratios (HRs) and their corresponding 95% confidence intervals (95%CIs) were reported for each outcome.</p><p>The tied events were managed using the Breslow method. The assumption of proportional hazards was tested using Schoenfeld residuals to ensure the validity of the Cox regression models. The statistical analyses were conducted using Stata/SE software version 17.0 (StataCorp), with a <italic toggle="yes">p</italic>-value &lt; 0.05 considered indicative of statistical significance.</p><p>This robust statistical approach allowed for the adjustment of potential confounders and ensured that the findings were both reliable and clinically meaningful.</p></sec></sec><sec sec-type="results" id="sec3-jpm-15-00089"><title>3. Results</title><p>Out of the 25,871 individuals enrolled in the VITAL study, 25,497 participants provided data on baseline aspirin use, while 394 individuals did not report such information. Among those who reported baseline aspirin use, 13,927 individuals did not use aspirin at baseline, whereas 11,570 individuals reported using aspirin at baseline (<xref rid="jpm-15-00089-f001" ref-type="fig">Figure 1</xref>).</p><p>The characteristics of the group of patients taking aspirin included age, sex, body mass index (BMI), race, smoking habits, and comorbidities (<xref rid="jpm-15-00089-t001" ref-type="table">Table 1</xref>). The aspirin users&#8217; mean age was 67.5 years (vs. 65.9 years in non-users, <italic toggle="yes">p</italic> &lt; 0.001), 54.7% were male (vs. 45.1%, <italic toggle="yes">p</italic> &lt; 0.001), and the mean BMI value was higher in aspirin users with 28.4 kg/m<sup>2</sup> compared with a mean BMI of 27.8 kg/m<sup>2</sup> in non-users (<italic toggle="yes">p</italic> &lt; 0.001). The number of current smokers amongst aspirin users was lower compared with aspirin non-users (6.2% versus 8.0%, <italic toggle="yes">p</italic> &lt; 0.001). At baseline, 58.5% of aspirin users had arterial hypertension treated with medication, significantly higher compared with aspirin non-users (42.1%, <italic toggle="yes">p</italic> &lt; 0.001). The aspirin users with diabetes mellitus were more frequent (17.7%) than diabetic individuals not treated with aspirin (10.3%; <italic toggle="yes">p</italic> &lt; 0.001). The usage of cholesterol-lowering medication and diabetes mellitus (DM) medication was also higher for patients under aspirin medication compared with patients who were not using aspirin (<xref rid="jpm-15-00089-t001" ref-type="table">Table 1</xref>).</p><p><xref rid="jpm-15-00089-t002" ref-type="table">Table 2</xref> shows the events and incidence rates within 5.3 years of follow-up according to the use of aspirin at baseline.</p><p>In the unadjusted analysis, the aspirin group presented a higher risk of cardiovascular mortality (HR 1.30, 95%CI 1.03 to 1.64) and cardiovascular events, such as major cardiovascular events (HR 1.21, 95%CI 1.03 to 1.64), coronary heart disease (HR 1.39, 95%CI 1.19 to 1.65), and stroke (HR 1.31, 95%CI 1.03 to 1.65) (<xref rid="jpm-15-00089-f002" ref-type="fig">Figure 2</xref>). However, after adjustingfor demographic and clinical variables, aspirin was not identified as a predictor of cardiovascular death (HR 1.17, 95%CI 0.89 to 1.55), major cardiovascular events (HR 1.04, 95%CI 0.89 to 1.22), coronary heart disease (HR 1.16, 95%CI 0.98 to 1.37), nor stroke (HR 1.01, 95%CI 0.77 to 1.31)&#8212;<xref rid="jpm-15-00089-f002" ref-type="fig">Figure 2</xref> and <xref rid="app1-jpm-15-00089" ref-type="app">Appendix A</xref>.</p><p>The adjusted HR for aspirin use in primary prevention varied by race/ethnicity (<xref rid="jpm-15-00089-t003" ref-type="table">Table 3</xref>). Among Caucasians, no significant differences were found for mortality (HR 0.86, 95%CI 0.74&#8211;1.04), CV mortality (HR 0.96, 95%CI 0.68&#8211;1.34), or MACE (HR 0.96, 95%CI 0.80&#8211;1.16). In Black participants, aspirin use was associated with a higher CV mortality (HR 2.01, 95%CI 1.10&#8211;3.68), while other outcomes were not significant. Results for Hispanic, Asian, and Native American groups were inconclusive due to wide confidence intervals or insufficient data. These findings suggest potential racial differences in aspirin&#8217;s effects, particularly in Black participants, warranting further investigation.</p></sec><sec sec-type="discussion" id="sec4-jpm-15-00089"><title>4. Discussion</title><p>The use of aspirin in primary prevention was not associated with the risk reduction of cardiovascular events, after adjustment for demographic and clinical characteristics, in this post hoc evaluation of the VITAL cohort data. It should be stressed that individuals with prescribed aspirin at baseline had an overall prevalence of clinical characteristics that predict a higher risk of cardiovascular events, such as increased age, male gender, higher BMI, and more frequent parental history of MI. These findings suggest that prescribing practices may have been influenced by clinicians&#8217; perception of risk, aligning with the principles of individualized care.</p><p>It is also important to contextualize these findings within the timeframe of data collection, which occurred over a decade ago when the evidence against aspirin in primary prevention was less definitive. This underscores the need for contemporary analyses that incorporate the advancements in personalized medicine, such as the integration of genetic and biomarker-based risk stratification, to guide more precise therapeutic decisions in primary prevention.</p><p>In 2009, a meta-analysis of randomized controlled trials suggested that aspirin use could reduce by 12% the risk of vascular events, mainly non-fatal MI, and suggested that aspirin could even have benefits in reducing all-cause mortality [<xref rid="B18-jpm-15-00089" ref-type="bibr">18</xref>]. However, it is plausible that these cardiovascular benefits reflected an era when cardiovascular risk factors were less effectively managed, leading to a higher relative benefit of antiplatelet therapy.</p><p>Over the past two decades, accumulating evidence has challenged the role of aspirin in primary prevention. Despite this growing evidence, a 2017 National Health Interview Survey revealed that 23.4% of individuals reported using aspirin for primary prevention, with 23% of these doing so without a physician&#8217;s recommendation [<xref rid="B19-jpm-15-00089" ref-type="bibr">19</xref>]. So, these findings highlight not only the need for continued physician education but also the importance of managing patient expectations and beliefs about the benefits and risks of aspirin. Incorporating personalized medicine approaches, such as individualized risk stratification and shared decision-making, could help bridge the gap between clinical evidence and patient behavior, optimizing the use of aspirin in primary prevention.</p><p>The main evidence against aspirin use in primary prevention came to light in 2018 with three important trials&#8212;the ASPREE trial (older adults) [<xref rid="B20-jpm-15-00089" ref-type="bibr">20</xref>], ASCEND trial (patients with diabetes) [<xref rid="B21-jpm-15-00089" ref-type="bibr">21</xref>], and ARRIVE study (average-risk adults) [<xref rid="B22-jpm-15-00089" ref-type="bibr">22</xref>]. Subsequently, systematic reviews have reached the same conclusions as our post hoc analysis in the general population, but also in specific groups of higher cardiovascular risk, such as those with diabetes or chronic kidney disease [<xref rid="B6-jpm-15-00089" ref-type="bibr">6</xref>,<xref rid="B7-jpm-15-00089" ref-type="bibr">7</xref>,<xref rid="B8-jpm-15-00089" ref-type="bibr">8</xref>,<xref rid="B23-jpm-15-00089" ref-type="bibr">23</xref>]. On the other hand, years after this change in paradigm, few studies still point in a different direction. For instance, Zhao et al. stated that low-dose aspirin should be considered for primary prevention in aboriginal people with high cardiovascular risk, due to reducing all-cause mortality (HR 0.45, 95%CI 0.34 to 0.60) and not significantly increasing bleeding risk (HR 1.13, 95%CI 0.39 to 3.26). We cannot extrapolate this data from people living in remote Australia with a mean age of only 42 years old to other urbanistic and older populations [<xref rid="B24-jpm-15-00089" ref-type="bibr">24</xref>]. This underscores the importance of personalized medicine in interpreting and applying clinical evidence.</p><p>Building on the principles of personalized medicine, it is essential to explore how factors such as race and ethnicity influence the effectiveness and safety of aspirin, shedding light on potential disparities in its cardiovascular benefits. Contrary to our results, other studies suggest that low-dose aspirin may not offer the same protective benefits for African Americans as it does for other populations. For instance, one study found that low-dose aspirin did not reduce the risk of fatal heart attacks among African Americans but showed a trend toward a decreased risk in white participants, especially women. Additionally, African Americans taking low-dose aspirin experienced an 18% increased risk of dying from a heart event, while non-Hispanic white participants had a 14% decreased risk [<xref rid="B25-jpm-15-00089" ref-type="bibr">25</xref>].</p><p>These disparities may stem from genetic variations affecting aspirin metabolism, poor control of cardiovascular risk factors, and differences in adherence to aspirin regimens. The medication interactions more common in African American populations could also play a role. Moreover, African Americans have been historically underrepresented in aspirin studies, limiting the applicability of findings to this population [<xref rid="B25-jpm-15-00089" ref-type="bibr">25</xref>].</p><p>Beyond biological factors, social and cultural influences may impact aspirin use and its outcomes. Positive peer support and cultural beliefs about aspirin have been linked to higher adoption rates in African American communities. The research in other contexts, such as cancer prevention, has also suggested that aspirin&#8217;s effects may vary across racial groups, further highlighting the need to explore these differences in cardiovascular prevention [<xref rid="B26-jpm-15-00089" ref-type="bibr">26</xref>].</p><p>These findings underscore the importance of more inclusive research to better understand the relationship between aspirin use, race/ethnicity, and cardiovascular outcomes. Addressing these disparities can guide the development of tailored prevention strategies and improve outcomes for underrepresented populations.</p><p>Another interesting topic regarding cardiovascular prevention is the great interest in simple approaches with wide applicability to address cardiovascular risk factors, including using fixed-dose combination drug regimens, also known as polypills. An individual participant data meta-analysis of three large randomized controlled trials (TIPS-3, HOPE-3, and Polylran) evaluated a fixed-dose combination strategy of at least two blood-pressure-lowering agents plus a statin with or without aspirin. The mean age of the participants was 63 &#177; 7.1 years old, and the estimated 10-year cardiovascular disease risk was 17.7 &#177; 8.7%. The group receiving fixed-dose combination strategies including aspirin had a 47% reduction (HR 0&#183;53, 95%CI 0&#183;41 to 0&#183;67; number needed to treat [NNT] 37) in the primary outcome (a composite of cardiovascular death, myocardial infarction, stroke, or arterial revascularization), compared with a 32% reduction (HR 0&#183;68, 95%CI 0&#183;57 to 0&#183;81; NNT 66) for fixed-dose combination strategies without aspirin. Regarding side effects related to aspirin, they were non-statistically different. This bundle strategy seems to be more effective in older patients (&gt;63 years old) with high or very-high CV risk (10-year CV risk &gt; 9.6%) [<xref rid="B27-jpm-15-00089" ref-type="bibr">27</xref>].</p><p>Despite this interesting putative beneficial effect of polypill regimen in a subgroup of patients, the current evidence of using aspirin alone in primary prevention in the general population does not seem to overcome the bleeding risk.</p><p>While our analysis provides valuable insights into this important topic, it is not without limitations. The VITAL trial/cohort, by including individuals who were willing to participate in a clinical trial aimed at reducing their cardiovascular disease (CVD) or cancer risk [<xref rid="B28-jpm-15-00089" ref-type="bibr">28</xref>], is subject to selection bias. However, it is noteworthy that almost half of the participants had hypertension, a third were on statin therapy, and 14% were diagnosed with diabetes. These cardiovascular risk factors were well represented in the study population, and the results were independent of these factors.</p><p>Another acknowledged limitation of our analysis is its retrospective and post hoc nature. Additionally, the lack of data regarding bleeding risk presents a significant drawback, as only hemorrhagic stroke outcomes were collected, showing no differences between groups. Nevertheless, given that no net benefit was observed with antiplatelet medication in this population, the absence of detailed bleeding risk data becomes less critical in this context.</p><p>These limitations highlight the importance of conducting prospective studies that incorporate personalized approaches, such as biomarker- or genetic-based risk stratification, to better define the role of aspirin in primary prevention. Such studies could refine therapeutic strategies and identify subgroups of patients who may derive the greatest benefit while minimizing potential harm.</p></sec><sec sec-type="conclusions" id="sec5-jpm-15-00089"><title>5. Conclusions</title><p>This retrospective/post hoc multivariate-adjusted (demographic and clinical characteristics) analysis of participants enrolled in the VITAL cohort did not show an association between aspirin use and reduced cardiovascular events in the setting of primary prevention.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.C.; Methodology, D.C.; Software, M.A.; Validation, J.J.F.; Formal analysis, D.C. and N.G.; Investigation, J.C. and F.J.P.; Resources, F.J.P.; Writing&#8212;original draft, D.C. and M.A.; Writing&#8212;review and editing, D.C., N.G., J.C., J.J.F., and F.J.P.; Visualization, M.A.; Supervision, F.J.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Ethical review and approval were waived for this study by the Ethics Committee of CAML (Centro Acad&#233;mico de Medicina de Lisboa) due to the retrospective data and anonymization.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was not required as the study involved the analysis of anonymized, retrospective data, in accordance with institutional and ethical guidelines.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original data presented in the study are available in the Project Data Sphere platform (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.34949/n4c7-zm25">https://doi.org/10.34949/n4c7-zm25</uri>).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>M.A. has taken part in educational meetings and has attended conferences or symposia, which included travel, accommodation, and hospitality provided by BIAL, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp &amp; Dohme, AstraZeneca, Tecnimede, and Bayer. D.C. has taken part in educational meetings and has attended conferences or symposia, which included travel, accommodation, and hospitality provided by Roche, BIAL, Pfizer, Bristol Myers Squibb, Ferrer, Bayer, Merck Serono, Boehringer Ingelheim, and Daiichi Sankyo. J.J.F. serves as a consultant for Merck Serono, Ipsen, GlaxoSmithKline, Solvay, Novartis, Lundbeck, Teva, Abbott, and BIAL. J.J.F. has also received grants from the MSD Foundation, Grunenthal, GlaxoSmithKline, and Teva. F.J.P. has received consultant and speaker fees from Daiichi Sankyo, Bayer, AstraZeneca, Boehringer Ingelheim, and BMS.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ASCVD</td><td align="left" valign="middle" rowspan="1" colspan="1">atherosclerotic cardiovascular disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACC</td><td align="left" valign="middle" rowspan="1" colspan="1">American College of Cardiology</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AHA</td><td align="left" valign="middle" rowspan="1" colspan="1">American Heart Association</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ESC</td><td align="left" valign="middle" rowspan="1" colspan="1">European Society of Cardiology</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VITAL</td><td align="left" valign="middle" rowspan="1" colspan="1">VITamins and Lifestyle</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TIA</td><td align="left" valign="middle" rowspan="1" colspan="1">transient ischemic attack</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CABG</td><td align="left" valign="middle" rowspan="1" colspan="1">coronary-artery bypass grafting</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MACE</td><td align="left" valign="middle" rowspan="1" colspan="1">major cardiovascular adverse event</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MI</td><td align="left" valign="middle" rowspan="1" colspan="1">myocardial infarction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHD</td><td align="left" valign="middle" rowspan="1" colspan="1">coronary heart disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TOAST</td><td align="left" valign="middle" rowspan="1" colspan="1">Trial of Org 10172 in Acute Stroke Treatment</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HR</td><td align="left" valign="middle" rowspan="1" colspan="1">hazard ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CI</td><td align="left" valign="middle" rowspan="1" colspan="1">confidence interval</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CVD</td><td align="left" valign="middle" rowspan="1" colspan="1">cardiovascular disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NNT</td><td align="left" valign="middle" rowspan="1" colspan="1">number needed to treat</td></tr></tbody></array></p></glossary><app-group><app id="app1-jpm-15-00089"><title>Appendix A</title><sec id="secAdot1-jpm-15-00089"><title>Appendix A.1</title><fig position="anchor" id="jpm-15-00089-f0A1" orientation="portrait"><label>Figure A1</label><caption><p>Kaplan-Meier curves for all-cause mortality, cardiovascular mortality, and major adverse cardiovascular event (MACE).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jpm-15-00089-g0A1.jpg"/></fig></sec></app></app-group><ref-list><title>References</title><ref id="B1-jpm-15-00089"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Meher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Seidler</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Askie</surname><given-names>L.M.</given-names></name></person-group><article-title>Antiplatelet agents for preventing pre-eclampsia and its complications</article-title><source>Cochrane Database Syst. Rev.</source><year>2019</year><volume>2019</volume><fpage>CD004659</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD004659.pub3</pub-id><pub-id pub-id-type="pmid">31684684</pub-id><pub-id pub-id-type="pmcid">PMC6820858</pub-id></element-citation></ref><ref id="B2-jpm-15-00089"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visseren</surname><given-names>F.L.J.</given-names></name><name name-style="western"><surname>MacH</surname><given-names>F.</given-names></name><name name-style="western"><surname>Smulders</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Carballo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Koskinas</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>B&#228;ck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benetos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Biffi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boavida</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Capodanno</surname><given-names>D.</given-names></name><etal/></person-group><article-title>2021 ESC Guidelines on cardiovascular disease prevention in clinical practice</article-title><source>Eur. Heart J.</source><year>2021</year><volume>42</volume><fpage>3227</fpage><lpage>3337</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab484</pub-id><pub-id pub-id-type="pmid">34458905</pub-id></element-citation></ref><ref id="B3-jpm-15-00089"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>J.L.</given-names></name></person-group><article-title>Rethinking Aspirin for the Primary Prevention of Cardiovascular Disease</article-title><source>Am. Fam. Physician</source><year>2019</year><volume>99</volume><fpage>670</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">31150176</pub-id></element-citation></ref><ref id="B4-jpm-15-00089"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marquis-Gravel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Roe</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Schuyler Jones</surname><given-names>W.</given-names></name></person-group><article-title>Revisiting the role of aspirin for the primary prevention of cardiovascular disease</article-title><source>Circulation</source><year>2019</year><volume>140</volume><fpage>1115</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.040205</pub-id><pub-id pub-id-type="pmid">31545683</pub-id></element-citation></ref><ref id="B5-jpm-15-00089"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nudy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ghahramani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruzieh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mandrola</surname><given-names>J.</given-names></name><name name-style="western"><surname>Foy</surname><given-names>A.J.</given-names></name></person-group><article-title>Aspirin for Primary Atherosclerotic Cardiovascular Disease Prevention as Baseline Risk Increases: A Meta-Regression Analysis</article-title><source>Am. J. Med.</source><year>2020</year><volume>133</volume><fpage>1056</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2020.04.028</pub-id><pub-id pub-id-type="pmid">32445718</pub-id></element-citation></ref><ref id="B6-jpm-15-00089"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldeira</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>M.</given-names></name><name name-style="western"><surname>David</surname><given-names>C.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>F.J.</given-names></name></person-group><article-title>Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis</article-title><source>Prim. Care Diabetes</source><year>2020</year><volume>14</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.pcd.2019.11.004</pub-id><pub-id pub-id-type="pmid">31791903</pub-id></element-citation></ref><ref id="B7-jpm-15-00089"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallikadavath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brunskill</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Major</surname><given-names>R.W.</given-names></name></person-group><article-title>Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis</article-title><source>Eur. J. Prev. Cardiol.</source><year>2021</year><volume>28</volume><fpage>1953</fpage><lpage>1960</lpage><pub-id pub-id-type="doi">10.1093/eurjpc/zwab132</pub-id><pub-id pub-id-type="pmid">34448849</pub-id></element-citation></ref><ref id="B8-jpm-15-00089"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calderone</surname><given-names>D.</given-names></name><name name-style="western"><surname>Greco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ingala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Agnello</surname><given-names>F.</given-names></name><name name-style="western"><surname>Franchina</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Scalia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buccheri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Capodanno</surname><given-names>D.</given-names></name></person-group><article-title>Efficacy and safety of aspirin for cardiovascular risk prevention in younger and older age: An updated systematic review and meta-analysis</article-title><source>Thromb. Haemost.</source><year>2022</year><volume>122</volume><fpage>445</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">34638150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1667-7427</pub-id></element-citation></ref><ref id="B9-jpm-15-00089"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbarawi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kheiri</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zayed</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gakhal</surname><given-names>I.</given-names></name><name name-style="western"><surname>Al-Abdouh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barbarawi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rashdan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rizk</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bachuwa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alkotob</surname><given-names>M.L.</given-names></name></person-group><article-title>Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials</article-title><source>High. Blood Press. Cardiovasc. Prev.</source><year>2019</year><volume>26</volume><fpage>283</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1007/s40292-019-00325-5</pub-id><pub-id pub-id-type="pmid">31280451</pub-id></element-citation></ref><ref id="B10-jpm-15-00089"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gelbenegger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Postula</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pecen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Halvorsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lesiak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schoergenhofer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jilma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hengstenberg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Siller-Matula</surname><given-names>J.M.</given-names></name></person-group><article-title>Aspirin for primary prevention of cardiovascular disease: A meta-analysis with a particular focus on subgroups</article-title><source>BMC Med.</source><year>2019</year><volume>17</volume><elocation-id>198</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-019-1428-0</pub-id><pub-id pub-id-type="pmid">31679516</pub-id><pub-id pub-id-type="pmcid">PMC6827248</pub-id></element-citation></ref><ref id="B11-jpm-15-00089"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ardoino</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rossio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blanca</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Nobili</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pasina</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mannucci</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Peyvandi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Franchi</surname><given-names>C.</given-names></name></person-group><article-title>Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people</article-title><source>Br. J. Clin. Pharmacol.</source><year>2017</year><volume>83</volume><fpage>2528</fpage><pub-id pub-id-type="doi">10.1111/bcp.13355</pub-id><pub-id pub-id-type="pmid">28722184</pub-id><pub-id pub-id-type="pmcid">PMC5651307</pub-id></element-citation></ref><ref id="B12-jpm-15-00089"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davidson</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Mangione</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Cabana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chelmow</surname><given-names>D.</given-names></name><name name-style="western"><surname>Coker</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Ja&#233;n</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Krist</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement</article-title><source>JAMA J. Am. Med. Assoc.</source><year>2022</year><volume>327</volume><fpage>1577</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.5207</pub-id><pub-id pub-id-type="pmid">35471505</pub-id></element-citation></ref><ref id="B13-jpm-15-00089"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cofer</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>J.S.</given-names></name></person-group><article-title>Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2022</year><volume>42</volume><fpage>1207</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.122.318020</pub-id><pub-id pub-id-type="pmid">36047408</pub-id><pub-id pub-id-type="pmcid">PMC9484763</pub-id></element-citation></ref><ref id="B14-jpm-15-00089"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manson</surname><given-names>J.A.E.</given-names></name><name name-style="western"><surname>Bassuk</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zaharris</surname><given-names>E.</given-names></name><name name-style="western"><surname>MacFadyen</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Danielson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease</article-title><source>Contemp. Clin. Trials</source><year>2012</year><volume>33</volume><fpage>159</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.cct.2011.09.009</pub-id><pub-id pub-id-type="pmid">21986389</pub-id><pub-id pub-id-type="pmcid">PMC3253961</pub-id></element-citation></ref><ref id="B15-jpm-15-00089"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>E.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Kristal</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Thornquist</surname><given-names>M.</given-names></name><name name-style="western"><surname>King</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shattuck</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>I.</given-names></name><name name-style="western"><surname>Satia-Abouta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Littman</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>J.D.</given-names></name></person-group><article-title>VITamins And Lifestyle Cohort Study: Study Design and Characteristics of Supplement Users</article-title><source>Am. J. Epidemiol.</source><year>2004</year><volume>159</volume><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1093/aje/kwh010</pub-id><pub-id pub-id-type="pmid">14693663</pub-id></element-citation></ref><ref id="B16-jpm-15-00089"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manson</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>I.-M.</given-names></name><name name-style="western"><surname>Christen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bassuk</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Mora</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Copeland</surname><given-names>T.</given-names></name><name name-style="western"><surname>D&#8217;Agostino</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1809944</pub-id><pub-id pub-id-type="pmid">30415629</pub-id><pub-id pub-id-type="pmcid">PMC6425757</pub-id></element-citation></ref><ref id="B17-jpm-15-00089"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldeira</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>F.J.</given-names></name></person-group><article-title>Aspirin in diabetic patients at primary prevention: Insights of the VITAL cohort</article-title><source>J. Endocrinol. Invest.</source><year>2023</year><volume>46</volume><fpage>1423</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1007/s40618-022-02001-3</pub-id><pub-id pub-id-type="pmid">36652191</pub-id><pub-id pub-id-type="pmcid">PMC10261209</pub-id></element-citation></ref><ref id="B18-jpm-15-00089"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hennekens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Doll</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bubes</surname><given-names>V.</given-names></name><name name-style="western"><surname>Buring</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dushkesas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gaziano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Meade</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>1849</fpage><lpage>1860</lpage><pub-id pub-id-type="pmid">19482214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(09)60503-1</pub-id><pub-id pub-id-type="pmcid">PMC2715005</pub-id></element-citation></ref><ref id="B19-jpm-15-00089"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Juraschek</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Wee</surname><given-names>C.C.</given-names></name></person-group><article-title>Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease in the United States: Results From the 2017 National Health Interview Survey</article-title><source>Ann. Intern. Med.</source><year>2019</year><volume>171</volume><fpage>596</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.7326/M19-0953</pub-id><pub-id pub-id-type="pmid">31330542</pub-id><pub-id pub-id-type="pmcid">PMC7251544</pub-id></element-citation></ref><ref id="B20-jpm-15-00089"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeil</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Tonkin</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Donnan</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Lockery</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kirpach</surname><given-names>B.</given-names></name><name name-style="western"><surname>Storey</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>1509</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1805819</pub-id><pub-id pub-id-type="pmid">30221597</pub-id><pub-id pub-id-type="pmcid">PMC6289056</pub-id></element-citation></ref><ref id="B21-jpm-15-00089"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mafham</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wallendszus</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>W.</given-names></name><name name-style="western"><surname>Buck</surname><given-names>G.</given-names></name><name name-style="western"><surname>Barton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aung</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>1529</fpage><lpage>1539</lpage><pub-id pub-id-type="pmid">30146931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1804988</pub-id></element-citation></ref><ref id="B22-jpm-15-00089"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaziano</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Brotons</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coppolecchia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cricelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Darius</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gorelick</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Rothwell</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Ruilope</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>1036</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31924-X</pub-id><pub-id pub-id-type="pmid">30158069</pub-id><pub-id pub-id-type="pmcid">PMC7255888</pub-id></element-citation></ref><ref id="B23-jpm-15-00089"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>So</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients&#8211;a longitudinal observational study</article-title><source>Cardiovasc. Diabetol.</source><year>2009</year><volume>8</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-8-57</pub-id><pub-id pub-id-type="pmid">19878541</pub-id><pub-id pub-id-type="pmcid">PMC2777137</pub-id></element-citation></ref><ref id="B24-jpm-15-00089"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jeyaraman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>P.</given-names></name><name name-style="western"><surname>Connors</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guthridge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maple-Brown</surname><given-names>L.</given-names></name><name name-style="western"><surname>Falhammar</surname><given-names>H.</given-names></name></person-group><article-title>All-cause mortality following low-dose aspirin treatment for patients with high cardiovascular risk in remote Australian Aboriginal communities: An observational study</article-title><source>BMJ Open</source><year>2020</year><volume>10</volume><fpage>e030034</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2019-030034</pub-id><pub-id pub-id-type="pmid">31900264</pub-id><pub-id pub-id-type="pmcid">PMC6955566</pub-id></element-citation></ref><ref id="B25-jpm-15-00089"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Jimenez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Fuster</surname><given-names>V.</given-names></name><name name-style="western"><surname>Blot</surname><given-names>W.J.</given-names></name></person-group><article-title>Low-dose aspirin for primary prevention of cardiovascular disease: Use patterns and impact across race and ethnicity in the southern community cohort study</article-title><source>J. Am. Heart Assoc.</source><year>2019</year><volume>8</volume><fpage>e013404</fpage><pub-id pub-id-type="doi">10.1161/JAHA.119.013404</pub-id><pub-id pub-id-type="pmid">31822218</pub-id><pub-id pub-id-type="pmcid">PMC6951082</pub-id></element-citation></ref><ref id="B26-jpm-15-00089"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erickson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Loffredo</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>George</surname><given-names>D.M.S.</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Deepak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Meaney</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Langenberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bernat</surname><given-names>D.H.</given-names></name><etal/></person-group><article-title>Racial and Ethnic Differences in the Relationship Between Aspirin Use and Non-Small Cell Lung Cancer Risk and Survival</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2018</year><volume>27</volume><elocation-id>1518</elocation-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-18-0366</pub-id><pub-id pub-id-type="pmcid">PMC6279562</pub-id><pub-id pub-id-type="pmid">30171037</pub-id></element-citation></ref><ref id="B27-jpm-15-00089"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roshandel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pais</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lonn</surname><given-names>E.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Avezum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sliwa</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: An individual participant data meta-analysis</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>1133</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01827-4</pub-id><pub-id pub-id-type="pmid">34469765</pub-id></element-citation></ref><ref id="B28-jpm-15-00089"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bassuk</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Manson</surname><given-names>J.A.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Christen</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Bubes</surname><given-names>V.Y.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Copeland</surname><given-names>T.</given-names></name><name name-style="western"><surname>Friedenberg</surname><given-names>G.</given-names></name><name name-style="western"><surname>D&#8217;Agostino</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL)</article-title><source>Contemp. Clin. Trials</source><year>2016</year><volume>47</volume><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/j.cct.2015.12.022</pub-id><pub-id pub-id-type="pmid">26767629</pub-id><pub-id pub-id-type="pmcid">PMC4818165</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jpm-15-00089-f001" orientation="portrait"><label>Figure 1</label><caption><p>Flowchart of patients from the VITAL (VITamins and Lifestyle) cohort study in analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jpm-15-00089-g001.jpg"/></fig><fig position="float" id="jpm-15-00089-f002" orientation="portrait"><label>Figure 2</label><caption><p>Hazard ratio with 95%CI of death and cardiovascular events unadjusted and adjusted for demographic and clinical variables. * Adjusted for age, sex, race, BMI, smoking, hypertension, parental history of myocardial infarction, diabetes mellitus, and the use of statins.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jpm-15-00089-g002.jpg"/></fig><table-wrap position="float" id="jpm-15-00089-t001" orientation="portrait"><object-id pub-id-type="pii">jpm-15-00089-t001_Table 1</object-id><label>Table 1</label><caption><p>Patients&#8217; demographic and clinical characteristics according to baseline use of aspirin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Aspirin&#8212;Yes (11,570)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Aspirin&#8212;No (13,927)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age (years) (mean, SD)</td><td align="center" valign="middle" rowspan="1" colspan="1">67.5 (6.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">65.9 (7.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sex (male) (%, n)</td><td align="center" valign="middle" rowspan="1" colspan="1">54.7 (6330)</td><td align="center" valign="middle" rowspan="1" colspan="1">45.1 (6282)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>) (mean, SD)</td><td align="center" valign="middle" rowspan="1" colspan="1">28.4 (5.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">27.8 (5.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Race/ethnic group (%, n)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="7" align="center" valign="middle" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Non-Hispanic white</td><td align="center" valign="middle" rowspan="1" colspan="1">74.8 (8446)</td><td align="center" valign="middle" rowspan="1" colspan="1">68.6 (9370)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Black</td><td align="center" valign="middle" rowspan="1" colspan="1">17.3 (1950)</td><td align="center" valign="middle" rowspan="1" colspan="1">22.4 (3061)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hispanic</td><td align="center" valign="middle" rowspan="1" colspan="1">3.5 (393)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.4 (603)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3 (147)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7 (235)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Native American or Alaskan</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 (118)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8 (107)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other/unknown</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1 (241)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 (273)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Current smoking (%, n)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.2 (711)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.0 (1113)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Parental history of MI (%, n)</td><td align="center" valign="middle" rowspan="1" colspan="1">17.8 (1837)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.3 (1765)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypertension treated with medication (%, n)</td><td align="center" valign="middle" rowspan="1" colspan="1">58.5 (6277)</td><td align="center" valign="middle" rowspan="1" colspan="1">42.1 (5827)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diabetes mellitus at baseline (%, n)</td><td align="center" valign="middle" rowspan="1" colspan="1">17.7 (2047)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.3 (1433)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline use of statins (%, n)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.8 (5258)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.8 (3571)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>SD&#8212;standard deviation; BMI&#8212;body mass index; MI&#8212;myocardial infarction.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jpm-15-00089-t002" orientation="portrait"><object-id pub-id-type="pii">jpm-15-00089-t002_Table 2</object-id><label>Table 2</label><caption><p>Number of events and incidence of outcomes according to aspirin use at baseline (follow-up period 5.3 years).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcomes</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Events<break/>n (%)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Incidence per 1000-PY<break/>(95%CI)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aspirin</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No Aspirin</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aspirin</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No Aspirin</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">All-cause mortality</td><td align="center" valign="middle" rowspan="1" colspan="1">443<break/>(3.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">508<break/>(3.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.2<break/>(6.6&#8211;7.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.9<break/>(6.4&#8211;7.6)</td></tr><tr><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">Cardiovascular mortality</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">146<break/>(1.3%)</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">134<break/>(1.0%)</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">2.4<break/>(2.0&#8211;2.8)</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">1.8<break/>(1.5&#8211;2.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MACE</td><td align="center" valign="middle" rowspan="1" colspan="1">396<break/>(3.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">391<break/>(2.8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5<break/>(5.9&#8211;7.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.4<break/>(4.9&#8211;6.0)</td></tr><tr><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">Expanded MACE</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">568<break/>(4.9%)</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">506<break/>(3.6%)</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">9.5<break/>(8.7&#8211;10.3)</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">7.0<break/>(6.4&#8211;7.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total MI</td><td align="center" valign="middle" rowspan="1" colspan="1">160<break/>(1.4%)</td><td align="center" valign="middle" rowspan="1" colspan="1">178<break/>(1.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6<break/>(2.3&#8211;3.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4<break/>(2.1&#8211;2.8)</td></tr><tr><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">Total CHD</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">358<break/>(3.1%)</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">310<break/>(2.2%)</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">5.9<break/>(5.3&#8211;6.6)</td><td align="center" valign="middle" style="background:#CCCCCC" rowspan="1" colspan="1">4.3<break/>(3.8&#8211;4.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total stroke</td><td align="center" valign="middle" rowspan="1" colspan="1">148<break/>(1.3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">135<break/>(1.0%)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4<break/>(2.1&#8211;2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.9<break/>(1.6&#8211;2.2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCCCCC" rowspan="1" colspan="1">Hemorrhagic stroke</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCCCCC" rowspan="1" colspan="1">20<break/>(0.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCCCCC" rowspan="1" colspan="1">22<break/>(0.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCCCCC" rowspan="1" colspan="1">0.33<break/>(0.21&#8211;0.51)</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#CCCCCC" rowspan="1" colspan="1">0.30<break/>(0.20&#8211;0.46)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jpm-15-00089-t003" orientation="portrait"><object-id pub-id-type="pii">jpm-15-00089-t003_Table 3</object-id><label>Table 3</label><caption><p>Adjusted hazard ratios (HRs) for all-cause mortality, cardiovascular mortality, and major adverse cardiovascular event (MACE), comparing aspirin vs. no aspirin, stratified by race/ethnicity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mortality</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CV Mortality</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MACE</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caucasian</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86 (0.74&#8211;1.04)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 (0.68&#8211;1.34)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 (0.80&#8211;1.16)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Black</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13 (0.80&#8211;1.61)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.01 (1.10&#8211;3.68)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.31 (0.86&#8211;1.98)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hispanic</td><td align="center" valign="middle" rowspan="1" colspan="1">0.78 (0.35&#8211;1.73)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.22 (0.02&#8211;2.01)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 (0.40&#8211;2.47)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" rowspan="1" colspan="1">1.80 (0.11&#8211;29.90)</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A *</td><td align="center" valign="middle" rowspan="1" colspan="1">1.16 (0.22&#8211;6.27)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Native American</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.30 (0.29&#8211;5.84)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.14 (0.52&#8211;8.76)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33 (0.05&#8211;2.25)</td></tr></tbody></table><table-wrap-foot><fn><p>* No events.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>